ATOSSA THERAPEUTICS, INC. — Director's Dealing 2019

Jan 15, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2019-01-13

Reporting Person: QUAY STEVEN C (Director, President & CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-13	Stock Option (Right to Buy)	$2.38	D	2300000	Disposed	2028-06-27	Common Shares (2300000)	Direct
2019-01-13	Stock Option (Right to Buy)	$1.36	A	2300000	Acquired	2029-01-13	Common Shares (2300000)	Direct

Footnotes

F1: The June 27, 2018 options are being rescinded and a new option is being granted in order to: (i) impose a shareholder-approval requirement for the new option grant, and (ii) remove the cash settlement feature and associated liability from the June 27, 2018 grant.

F2: Twenty-five percent of the options were vested as of the grant date (June 27, 2018), 50% of the options will vest quarterly over two years from the grant date, and the remaining 25% will vest upon achievement of certain milestones.

F3: Subject to stockholder approval of the option grant, the option will vest and be exercisable with respect to: (i) 25% of the underlying shares as of the grant date (January 13, 2019), (ii) 50% of the underlying shares over a two-year period (vesting ratably quarterly) from June 27, 2018, and (iii) 25% of the underlying shares upon achievement of certain milestones. If the option grant is not approved by stockholders, then the option will not be exercisable.